http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 03:55:56 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Mizuho+Reiterates+Outperform+Rating+on+Alkermes+%28ALKS%29/27007601.html <p>Mizuho analyst Vamil Divan reiterated an Outperform rating and $65.00 price target on Alkermes (NASDAQ: ALKS).</p><p>The analyst comments "Given the level of inbound, we consulted with KOLs to gauge their expectations for ALKS-7290 Phase 1b readout in adult ADHD, expected this quarter. Given the inadequate powering (small sample, n=50), the KOLs don't expect ALKS-7290 to demonstrate statistical significance on efficacy measures (AISRS/relevant neuropsychological tests) but would like to see meaningful improvements over placebo. However, KOLs underscored that standard-of-care stimulants are highly effective and set a high efficacy bar, but they believe ALKS-7290 could potentially differentiate on overall safety/tolerability profile based http://www.streetinsider.com/Analyst+Comments/Mizuho+Reiterates+Outperform+Rating+on+Alkermes+%28ALKS%29/27007601.html Tue, 01 Sep 2026 03:55:56 -0400 ALKS http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html <p>Alkermes plc (Nasdaq: ALKS) announced the publication of phase 2 clinical trial data for its investigational drug alixorexton in <i>The Lancet Neurology</i>, covering results from the Vibrance-1 study in adults with narcolepsy type 1 (NT1).</p> <p>The study enrolled 92 adults with NT1 in a six-week, randomized, placebo-controlled, double-blind period. Participants received once-daily doses of alixorexton at 4 mg, 6 mg, or 8 mg, or placebo. All three dose groups achieved mean sleep latency values within the normative range on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week six. Weekly cataplexy rate was significantly reduced versus placebo in the http://www.streetinsider.com/FDA/Alkermes+narcolepsy+drug+data+published+in+The+Lancet+Neurology/26969412.html Mon, 24 Aug 2026 18:30:15 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Press+Releases/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html <p class="bwalignc"> <i>– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy –</i> </p><p class="bwalignc"> <i>– At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and Health-Related Quality of Life –</i> </p><p class="bwalignc"> <i>– Alixorexton Was Generally Well Tolerated at All Doses Tested –</i> </p> <p> DUBLIN--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alkermes.com%2F&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=Alkermes+plc&amp;index=1&amp;md5=69cc8a94df02997b1f0f71e46213844a" shape="rect">Alkermes plc</a> (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flaneur%2Farticle%2FPIIS1474-4422%252826%252900278-4%2Ffulltext&amp;esheet=54593896&amp;newsitemid=20260824378408&amp;lan=en-US&amp;anchor=The+Lancet+Neurology&amp;index=2&amp;md5=c80705af8817105f948d2c0369d5703c" shape="rect"><i>The Lancet Neurology</i></a>. Alixorexton is a novel, investigational, oral, selective orexin http://www.streetinsider.com/Business+Wire/The+Lancet+Neurology+Publishes+Data+From+Alkermes%E2%80%99+Positive+Vibrance-1+Phase+2+Study+of+Alixorexton+in+Adults+With+Narcolepsy+Type+1/26969410.html Mon, 24 Aug 2026 18:30:00 -0400 A.06822034 A.60012004 ALKS O.01304637 O.11483015 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+17++Filed+by%3A+Nichols+Christian+Todd/26939228.html si-local-file:///var/storage/secattach/20260817/26939228.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+17++Filed+by%3A+Nichols+Christian+Todd/26939228.html Mon, 17 Aug 2026 18:54:00 -0400 ALKS O.11483015 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+17++Filed+by%3A+Nichols+Christian+Todd/26939228.html si-local-file:///var/storage/secattach/20260817/26939228.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+17++Filed+by%3A+Nichols+Christian+Todd/26939228.html Mon, 17 Aug 2026 18:54:00 -0400 ALKS O.11483015 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Alkermes+plc.++++++++++++++++++++++++++Filed+by%3A+Nichols+Christian+Todd/26938643.html si-local-file:///var/storage/secattach/20260817/26938643.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Alkermes+plc.++++++++++++++++++++++++++Filed+by%3A+Nichols+Christian+Todd/26938643.html Mon, 17 Aug 2026 16:50:00 -0400 ALKS O.11483015 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Alkermes+plc.++++++++++++++++++++++++++Filed+by%3A+Nichols+Christian+Todd/26938643.html si-local-file:///var/storage/secattach/20260817/26938643.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Alkermes+plc.++++++++++++++++++++++++++Filed+by%3A+Nichols+Christian+Todd/26938643.html Mon, 17 Aug 2026 16:50:00 -0400 ALKS O.11483015 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Gaffin+David+Joseph/26910832.html si-local-file:///var/storage/secattach/20260812/26910832.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Gaffin+David+Joseph/26910832.html Wed, 12 Aug 2026 11:03:00 -0400 ALKS O.11483015 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Gaffin+David+Joseph/26910832.html si-local-file:///var/storage/secattach/20260812/26910832.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alkermes+plc.+++++++++++++For%3A+Aug+03++Filed+by%3A+Gaffin+David+Joseph/26910832.html Wed, 12 Aug 2026 11:03:00 -0400 ALKS O.11483015